Total | 173 | 100 |
Adverse events possibly related to mepolizumab n | 159 | 99 |
General disorders and administration site conditions | 62 (39.0) | 46 |
Nervous system disorders | 24 (15.1) | 20 |
Respiratory, thoracic and mediastinal disorders | 21 (13.2) | 13 |
Gastrointestinal disorders | 14 (8.8) | 10 |
Musculoskeletal and connective tissue disorders | 10 (6.3) | 7 |
Skin and subcutaneous tissue disorders | 9 (5.7) | 9 |
Vascular disorders | 5 (3.1) | 4 |
Infections and infestations | 3 (1.9) | 2 |
Injury, poisoning and procedural complications# | 2 (1.3) | 2 |
Renal and urinary disorders | 2 (1.3) | 2 |
Cardiac disorders | 1 (0.6) | 1 |
Ear and labyrinth disorders | 1 (0.6) | 1 |
Eye disorders | 1 (0.6) | 1 |
Immune system disorders | 1 (0.6) | 1 |
Investigations | 1 (0.6) | 1 |
Pregnancy, puerperium and perinatal conditions | 1 (0.6) | 1 |
Reproductive system and breast disorders | 1 (0.6) | 1 |
Serious adverse events possibly related to mepolizumab n | 14 | 8 |
Respiratory, thoracic and mediastinal disorders | 4 (28.6) | 2 |
Musculoskeletal and connective tissue disorders | 3 (21.4) | 1 |
General disorders and administration site conditions | 2 (14.3) | 2 |
Nervous system disorders | 2 (14.3) | 2 |
Infections and infestations | 2 (14.3) | 2 |
Hepatobiliary disorders | 1 (7.1) | 1 |
Most common drug-related adverse and serious adverse events possibly related to mepolizumab (n≥5%) | | |
Drug ineffective | 31 (17.9+) | 30 |
Headache | 14 (8.1+) | 14 |
Asthma¶ | 13 (7.5+) | 3 |
Asthenia | 12 (6.9+) | 12 |